A5073988252- Immune cells in cancer
- Liver physiology and pathology
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Glioma Diagnosis and Treatment
- Adenosine and Purinergic Signaling
Chinese University of Hong Kong
2023-2024
Objective Therapy-induced tumour microenvironment (TME) remodelling poses a major hurdle for cancer cure. As the majority of patients with hepatocellular carcinoma (HCC) exhibits primary or acquired resistance to antiprogrammed cell death (ligand)-1 (anti-PD-[L]1) therapies, we aimed investigate mechanisms underlying adaptation immune-checkpoint targeting. Design Two immunotherapy-resistant HCC models were generated by serial orthotopic implantation cells through anti-PD-L1-treated...
Genomic screening uncovered interferon-gamma (IFNγ) pathway defects in tumours refractory to immune checkpoint blockade (ICB). However, its non-mutational regulation and reversibility for therapeutic development remain less understood.
Recent studies demonstrated the importance of fibrosis in promoting an immunosuppressive liver microenvironment and thereby aggressive hepatocellular carcinoma (HCC) growth resistance to immune checkpoint blockade (ICB), particularly via monocyte-to-monocytic myeloid-derived suppressor cell (M-MDSC) differentiation triggered by hepatic stellate cells (HSCs). We thus aimed identify druggable targets these myeloid for HCC therapy.